Loading...
XNAS
NEPH
Market cap35mUSD
Jul 09, Last price  
3.50USD
1D
5.74%
1Q
18.24%
Jan 2017
6.22%
IPO
159.26%
Name

Nephros Inc

Chart & Performance

D1W1MN
XNAS:NEPH chart
P/E
31.82
P/S
2.02
EPS
0.11
Div Yield, %
Shrs. gr., 5y
3.85%
Rev. gr., 5y
17.02%
Revenues
19m
+32.67%
793,4891,196,0001,473,0002,661,0002,938,0002,214,0001,807,0001,740,0001,748,0001,944,0002,320,0003,809,0005,687,00010,334,0008,561,00010,217,0009,975,00014,238,00014,162,00018,789,000
Net income
1m
+1,513.51%
-8,012,911-26,356,000-6,337,000-2,026,000-1,933,000-2,360,000-3,262,000-3,698,000-7,371,000-3,088,000-3,032,000-809,000-3,402,000-3,420,000-4,766,000-4,107,000-7,382,000-1,575,00074,0001,194,000
CFO
2m
P
-7,299,597-7,434,000-5,725,000-2,612,000-1,292,000-1,296,000-1,547,000-3,583,000-2,495,000-3,815,000-2,112,000-77,000-3,662,000-2,276,000-6,903,000-1,417,000-3,234,000827,000-492,0001,645,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Nephros, Inc. is a company that specializes in developing and marketing sophisticated water purification solutions across the United States, catering to both the medical and commercial sectors. Its operations are structured into three primary segments: Water Filtration, Pathogen Detection, and Renal Products. Within its Water Filtration division, Nephros offers advanced ultrafiltration products. These are vital in dialysis centers for eradicating biological contaminants from water and bicarbonate concentrate, and are also deployed in hospitals to prevent infections from waterborne pathogens such as Legionella and Pseudomonas. Their utility extends to military installations, outdoor recreation, commercial establishments, and various other healthcare facilities. The Pathogen Detection segment focuses on developing and distributing real-time water testing systems, which deliver critical, actionable data regarding waterborne pathogens. Furthermore, under its Renal Products segment, the company provides medical devices designed for individuals suffering from renal disease, notably including a second-generation hemodiafiltration system tailored for patients with end-stage renal disease. Additionally, Nephros markets a range of water filters under the Nephros and AETHER brands. These filters are engineered not only to enhance water taste and eliminate odors but also to significantly reduce biofilm, bacteria, and scale accumulation in downstream equipment, serving the food service, hospitality, convenience store, and healthcare industries. Established in 1997, Nephros, Inc. maintains its corporate headquarters in South Orange, New Jersey.
IPO date
Sep 21, 2004
Employees
27
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT